Impact of metformin & serratiopeptidase in obese patients with knee osteoarthritis
Knee osteoarthritis is a common disabling chronic disease globally. Many pharmacological agents have been used efficiently in treatment of knee osteoarthritis.
This study aims to evaluate metformin &serratiopeptidase together in treatment and stop of osteoarthritis progression by different mechanisms
Present study was a randomized clinical trial study conducted in Al-Kindi teaching hospital through the period from 1st January to 30th of May, 2017 on two groups of 80 osteoarthritis patients (group I; treated with metformin 850 mg oral tablets) and (group II; treated with metformin 850 mg oral tablets & serratiopepitidase 20 mg oral tablets). Parameters of two groups were compared with those of 40 normal healthy controls
A total of 80 patients with knee OA were selected non-randomly and were randomized digitally into two groups (group I; treated with metformin 850 mg oral tablets) and (group II; treated with metformin 850 mg oral tablets & serratiopepitidase 20 mg oral tablets). The patients with knee OA were diagnosed clinically and radiological by Rheumatologist in Al-Kindi teaching hospital. A group of 40 healthy controls was selected from relatives of patients. The weight and height of each all study participants (n=120) was measured using calibrated scale to calculate the body mass index (BMI) before selection in the study. All the study participants were matched for BMI.
Licensing
from 1st January to 30th of May, 2017
No CN patents
Iraq
